SAN DIEGO, July 11, 2016 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the second quarter 2016 on Tuesday, August 9, 2016 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date post-market, Halozyme will release financial results for
the second quarter 2016.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please visit
www.halozyme.com approximately fifteen minutes prior to the call to
register, download and install any necessary audio software. The
live call may be accessed by calling (877) 410-5657 (domestic
callers) or (334) 323-7224 (international callers) using passcode
769890. A telephone replay will be available after the call by
dialing (877) 919-4059 (domestic callers) or (334) 323-0140
(international callers) using replay ID number 79675248.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug PEGPH20,
applies a unique approach to targeting solid tumors, allowing
increased access of co-administered cancer drug therapies to the
tumor in animal models. PEGPH20 is currently in development for
metastatic pancreatic cancer, non-small cell lung cancer, gastric
cancer, metastatic breast cancer and has potential across
additional cancers in combination with different types of cancer
therapies. In addition to its proprietary product portfolio,
Halozyme has established value-driving partnerships with leading
pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen,
AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme
is headquartered in San Diego. For
more information visit www.halozyme.com.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-host-second-quarter-2016-financial-results-conference-call-300296670.html
SOURCE Halozyme Therapeutics, Inc.